This inventor holds 11 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignees: Eli Lilly and Company, Ligand Pharmaceuticals, Inc.. Active years: 2007-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Indianapolis, IN (US) (2007 - 2009)
- Fishers, IN (US) (2010 - 2016)
Company Filing History:
11 out of 4,514 
1 out of 139 
Years Active: 2007-2016
Title: **Kevin Matthew Gardinier: Innovator in Pharmaceutical Chemistry**
Introduction
Kevin Matthew Gardinier is a prominent inventor and researcher located in Fishers, IN, USA. With a noteworthy contribution to the field of pharmaceutical chemistry, he holds a total of 11 patents that showcase his innovative spirit and dedication to advancing medical science.
Latest Patents
Among his latest patents, Gardinier has developed a TARP γ8 dependent AMPA receptor antagonist, which presents a unique formula that includes variables for both carbon and nitrogen. This invention details its pharmaceutically acceptable salts, various uses, and methods for preparation. Another significant contribution is his work on melanin concentrating hormone antagonists, focusing on compounds useful in treating obesity and related diseases. These compounds are described with a complex formula and accommodate various forms like salts, enantiomers, and diastereomers.
Career Highlights
Kevin Gardinier's professional trajectory includes pivotal roles at reputable companies such as Eli Lilly and Company and Ligand Pharmaceuticals, Inc. His work at these organizations has been instrumental in the development of innovative therapeutic compounds that address critical health issues.
Collaborations
Throughout his career, Gardinier has collaborated with notable colleagues, including Albert Kudzovi Amegadzie and Erik James Hembre, II. These partnerships demonstrate his ability to work within dynamic teams to pioneer advancements in biotechnology and pharmaceuticals.
Conclusion
Kevin Matthew Gardinier's contributions to the field of pharmaceutical chemistry not only highlight his individual ingenuity but also reflect the collaborative efforts that drive innovation. His 11 patents represent a significant legacy in the pursuit of effective treatments for challenging medical conditions. Gardinier continues to stand out as a key inventor in his field, making strides that will surely impact future generations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile